• A S Merseburger, M A Kuczyk, and J M Wolff.
• Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Carl Neuberg Straße 1, Hannover, Germany. merseburger.axel@mh-hannover.de
• Urologe A. 2013 Feb 1; 52 (2): 219-25.

AbstractAdvanced prostate cancer that progresses under androgen deprivation therapy has long been thought to be refractory to further hormonal treatment. The identification of the mechanism of cancer cells has revolutionized this understanding. Today it is known that castration-resistant prostate cancer (CRPC) still receives signals through the androgen receptor transduction pathways and furthermore is sensitive to hormone therapy. New substances, such as abiraterone, enzalutamide (MDV3100) and TAK 700 target these mechanisms of resistance of cancer cells, stop testosterone production and show not only better tolerance but also effective antitumor activity. Due to the heterogeneity of tumors with cells in varying states of differentiation, the treatment of CRPC with androgen deprivation therapy remains a cornerstone of disease management. To what extent the experimental findings and the recommendations in the guidelines are put into practice was the subject of a survey among urologists analyzing their treatment strategies with CRPC patients.

38 keywords...

hide…